Biocon gained 2.91% to Rs 270.75 after the company has signed a licensing and supply agreement with Biomm S.A., for the commercialization of Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.
| Subscribe To Our Free Newsletter |
